- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00140803
Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, single-masked (VA examiners, angiographic graders), multi-center, Phase 2 study with 3 arms comparing VISUDYNE therapy in combination with intravitreal injection of either a 1 mg or 4 mg of triamcinolone with VISUDYNE therapy without intravitreal triamcinolone in a 1:1:1 ratio.
Re-treatment may be administered at 3 month intervals ( 14 days) if evidence of CNV leakage is detected by fluorescein angiography.
At baseline and at 3 month (+ 14 days) intervals patients will undergo the following assessments: ophthalmic examination, best corrected visual acuity, fluorescein angiography, and color fundus photography. The eligibility criteria for inclusion into the study and re-treatment of patients will be based on fluorescein angiography. Patients receiving treatment at day-1, week-3, and week-6 following the treatment will have best corrected ETDRS visual acuity testing and ophthalmic. Those patients not being re-treated will have will have best corrected ETDRS visual acuity testing and ophthalmic examination at week-6 following the re-treatment evaluation visit.
Adverse events will be assessed throughout the study.
Expected time for recruitment is 6 months; all patients will be followed for the period of 12 months in the study
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 3N9
- Vh/UBC Eye Care Centre
-
-
-
-
New York
-
New York, New York, United States, 10021
- Manhattan Eye, Ear & Throat Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Age 50 years or older
- Subfoveal CNV secondary to age-related macular degeneration
- Area of the CNV at least 50% of the area of the total neovascular lesion
- The lesion is either minimally classic or occult with no classic
- If the lesion is occult with no classic then subjects must have presumed recent disease progression in the study eye in the judgment of the Investigator and as defined by presence of blood associated with the lesion or vision loss or lesion growth reported or objectively recorded within the preceding 3 months before randomization to treatment
- Baseline BCVA score between 73 and 19 letters on the ETDRS scale (approximately 20/40 to 20/400)
- Lesion size < 5400 microns
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
Subjects may not be randomized to treatment if they:
- Have evidence of predominantly classic CNV, clinically significant intraocular inflammation, angioid streaks, presumed ocular histoplasmosis syndrome, axial myopia greater than -6 diopters, or other precursors of choroidal neovascularization
- Have additional eye disease that compromises the visual acuity of the study eye.
- Are receiving or require chronic concomitant therapy with systemic or topical ocular corticosteroids or NSAIDS. Chronic concomitant therapy is defined as multiple doses taken daily for 3 or more consecutive days at any time during the course of the 12-month study). A low dose (up to 100 mg po qd) of aspirin (ASA) taken for prophylaxis of MI and/or stroke is permitted during the study.
- Are using coumadin.
- Have known hypersensitivity to verteporfin or triamcinolone
- Have CNV that does not involve the geometric center of the foveal avascular zone, as determined by color photography and fluorescein angiography
- Are unable to be photographed to document CNV, e.g. due to media opacity, allergy to fluorescein dye or lack of venous access
- Have lens opacities which, in the investigator's opinion, would progress during the course of the study and would affect central vision in the study eye. Such cataracts may be removed at least 2 months before entering the subject in the study
- Have a history of treatment for CNV, other than confluent laser photocoagulation, in the study eye (e.g., PDT, submacular surgery, radiotherapy or macular scatter "grid" laser photocoagulation
- Are participating in another clinical trial requiring follow-up examinations or are receiving or have received any experimental treatment for CNV or any other investigational new drug within 12 weeks prior to the start of study treatment
- Have an intraocular pressure greater than 21 mm Hg on or off medication on entry to the study.
- Have received prior treatment with another anti-angiogenic compound (e.g., Sandostatin®, LY333531, Macugen, RhuFab, etc.) within 6 months prior to screening
- Are unwilling or unable to follow or comply with all study-related procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective of this study is to determine the effect of Visudyne therapy in combination with 4 mg intravitreal triamcinolone on the mean change in BCVA at Month 12.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Proportion of patients having a 15 letter (3 lines) loss or more in BCVA
Time Frame: 12 months
|
12 months
|
• Proportion of patients having a 15 letter (3 lines) improvement or more in BCVA
Time Frame: 12 months
|
12 months
|
• Proportion of patients requiring re-treatment at any time during the study
Time Frame: 12 months
|
12 months
|
• The number of re-treatments required
Time Frame: 12 months
|
12 months
|
• Difference in treatment effect between 1 mg and 4 mg of triamcinolone acetonide
Time Frame: 12 months
|
12 months
|
• The change in MNREAD score
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Richard F. Spaide, MD, Manhattan Eye, Ear & Throat Hospital
Study record dates
Study Major Dates
Study Start
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Photosensitizing Agents
- Dermatologic Agents
- Verteporfin
- Triamcinolone Acetonide
Other Study ID Numbers
- VISTA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
Clinical Trials on Kenalog
-
Cale JacobsVanderbilt UniversityCompleted
-
University of MinnesotaCompletedAlopecia AreataUnited States
-
HaEmek Medical Center, IsraelUnknownThyroid Disease
-
Rutgers, The State University of New JerseyTerminated
-
University of MinnesotaNational Alopecia Areata FoundationCompletedAlopecia AreataUnited States
-
Steward St. Elizabeth's Medical Center of Boston...Terminated
-
University of North Carolina, Chapel HillCompletedHidradenitis SuppurativaUnited States
-
Foundation for Orthopaedic Research and EducationFlorida Orthopaedic InstituteRecruitingKnee OsteoarthritisUnited States
-
Henry Ford Health SystemCompletedTo Assess the Changes in Markers of Bone Turnover Over a Six Month Period After Epidural Steroid Inject | To Assess the Changes in Bone Mineral DensityUnited States
-
Keesler Air Force Base Medical CenterCompleted